Ultrasound-guided Pectoral Nerve Blocks, Thoracic Erector Spinae Plane Block and Serratus Anterior Plane Block for Breast Surgery

NCT06947642 | Recruiting

• 1 other identifier: 36265MD276/9/24
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The study will compare ultrasound-guided Pectoral nerve block, Erector Spinae Plane block, and Serratus anterior plane block for pain management following elective breast surgeries

Conditions

Ultrasound; Pectoral Nerve Blocks; Thoracic Erector Spinae Plane Block; Serratus Anterior Plane Block; Breast Surgery

Outcome Measures

Primary Outcomes (1)

• Total morphine consumption

  Rescue analgesia of morphine will be given as 3 mg bolus if the visual analogue scale (VAS) ≥ 4 to be repeated after 30 min if pain persists until the VAS\< 4.

  24 hours postoperatively

Secondary Outcomes (7)

• Time to the 1st rescue analgesia

  24 hours postoperatively

• Intraoperative fentanyl consumption

  Intraoperatively

• Pain degree

  24 hours postoperatively

• Mean arterial blood pressure

  Till the end of surgery (Up to 24hours)

• Heart rate

  Till the end of surgery (Up to 24hours)

Study Arms (3)

Pectoral nerve block (PECS)

EXPERIMENTAL

Patients will receive pectoral nerve block (PECS).

Drug: Pectoral nerve block (PECS)

Erector spinae plane block (ESP)

EXPERIMENTAL

Patients will receive erector spinae plane block (ESP).

Drug: Erector spinae plane block (ESP)

Serratus anterior plane block (SAP)

EXPERIMENTAL

Patients will receive serratus anterior plane block (SAP).

Drug: Serratus anterior plane block (SAP)

Interventions

Pectoral nerve block (PECS) DRUG

Patients will receive pectoral nerve block (PECS).

Also known as: Bupivacaine 0.25

Pectoral nerve block (PECS)

Erector spinae plane block (ESP) DRUG

Patients will receive erector spinae plane block (ESP).

Also known as: Bupivacaine 0.25

Erector spinae plane block (ESP)

Serratus anterior plane block (SAP) DRUG

Patients will receive serratus anterior plane block (SAP).

Also known as: Bupivacaine 0.25

Serratus anterior plane block (SAP)

Eligibility Criteria

• Age: 21 Years - 65 Years
• Gender Eligibility Details: Female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age from 21 to 65 years old female, American Society of Anesthesiologists (ASA) physical status I or II, who will undergo breast surgeries under general anesthesia.

You may not qualify if:

• Patient refusal to participate in research.
• Body Mass Index (BMI) ≥35 kg/m2.
• Sensitivity to the intervention drugs.
• Coagulation abnormalities.
• Psychiatric disorder and communication difficulties.
• Chronic neurological disease.
• Any skin infection at the needle puncture site.
• Chest wall deformity

Sponsors & Collaborators

• Tanta University: lead

Study Sites (1)

Tanta University

Tanta, El-Gharbia, 31527, Egypt

RECRUITING

Central Study Contacts

Rehab S Taha, Master

CONTACT

00201000507975; rehabsalah2017@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Lecturer of Anesthesiology, Surgical Intensive Care and Pain Management Department, Faculty of Medicine, Tanta University, Tanta, Egypt.

Study Record Dates

• First Submitted: April 20, 2025
• First Posted: April 27, 2025
• Study Start: April 30, 2025
• Primary Completion (Estimated): September 30, 2026
• Study Completion (Estimated): September 30, 2026
• Last Updated: May 20, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will share
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)